LOGIN
ID
PW
MemberShip
2023-01-29 01:57
All News
Policy
Company
Product
Opinion
InterView
°Ë»ö
Dailypharm Live Search
Close
Company
HK inno.N introduces biosimilar for Prolia & Xgeva
by
Lee, Seok-Jun
Jan 27, 2023 05:51am
HK inno.N announced on the 25th that it has signed an exclusive license contract for Denosumab biosimilar, a treatment for preventing osteoporosis and cancer-related skeletal complications in Mabxience, Spain. HK inno.N will receive an exclusive supply of two Denosumab biosimilars from Mabxience to apply for and sell domestic licenses. Denosu
Company
Flu activity rises...revives Tamiflu market
by
Jan 27, 2023 05:51am
The influenza treatment market, which had virtually disappeared after the spread of COVID-19, has revived for the first time in 3 years. With the number of flu patients surging due to the flu epidemic, the number of quarterly prescriptions soared from less than KRW 100 million to KRW 10 billion. According to the market research institution UB
Company
Will the 3 asthma biodrugs finally be reimbursed this year?
by
Eo, Yun-Ho
Jan 27, 2023 05:50am
Whether the 3 new biologics for asthma will be listed for insurance reimbursement in Korea is receiving attention. According to industry sources, treatments for severe asthma including GSK Korea¡¯s Nucala (mepolizumab), Teva-Handok¡¯s Cinqair (reslizumab), and AstraZeneca Korea¡¯s Fasenra (benralizumab) are undergoing processes for reimbu
Company
JAKi Cibinqo attempts reimb in both adolescents and adults
by
Eo, Yun-Ho
Jan 26, 2023 06:06am
Pfizer is attempting to receive approval to reimburse its JAK inhibitor ¡®Cibinqo¡¯ in atopic dermatitis (AD) for both adults and adolescents in Korea. According to industry sources, Pfizer Korea resubmitted an application for the reimbursement approval of its new janus kinases (JAK) inhibitor ¡®Cibinqo (abrocitinib)¡¯ at the end of last
Company
54 billion won ⟵ 3.7 billion won in four years
by
Kim, Jin-Gu
Jan 26, 2023 06:06am
In the high blood pressure and hyperlipidemia complex market, the pace of generational replacement between the second and third complexes is accelerating. The size of outpatient prescriptions for the third-party complex of the ARB+CCB+statin combination has tripled in the past three years, expanding to the market of more than 50 billion won a
Company
Medytox in legal dispute with its Chinese partner
by
Kim, Jin-Gu
Jan 25, 2023 06:08am
Medytox has been embroiled in a 120 billion won legal dispute with its Chinese botulinum toxin partner. Medytox officially announced on the 20th that Gentix Ltd., a subsidiary of the Chinese company Bloomage Biotechnology, had filed a claim for damages against Medytox to the Singapore International Arbitration Centre (SIAC). Genti
Company
LG Chem completes acquisition of US bio-company AVEO
by
Kim, Jin-Gu
Jan 20, 2023 06:07am
LG Chem has completed the acquisition of the US bio-company AVEO Pharmaceuticals and plans to make the leap to become one of the 'global top 30 pharmaceutical companies focusing on the oncology business. On the 19th, LG Chem announced that it had invested KRW 707.2 billion (USD 571 million) in its U.S. affiliate, ¡®LG Chem Life Science
Company
Anti-depressant Brintellix generic for exclusivity succeeded
by
Jan 20, 2023 06:07am
Myungin Pharmaceutical (CEO Lee Dong-myung) and Unimmed Pharmaceutical (CEO Kim Gun-nam) announced on the 18th that they succeeded in invalidating the patent for the antidepressant Brintellix. The Korean Intellectual Property Tribunal recently made a decision to cite the claim on Brintellix purpose patents filed by both companies against Lund
Company
The Brain disease prescription market disappears
by
Chon, Seung-Hyun
Jan 19, 2023 05:59am
Pharmaceutical companies lost 30 billion won a year due to Oxiracetam. Prescription loss became a reality as it failed to prove its efficacy in an eight-year clinical re-evaluation. Following acetyl-L-Carnitin last year, the annual prescription market worth 100 billion won has disappeared due to the failure of clinical re-evaluation of cerebr
Company
Generic drugs occupy 41% of antidiabetics market in 9 mths
by
Kim, Jin-Gu
Jan 19, 2023 05:58am
Generic products of off-patent drugs are quickly increasing their influence In the DPP-4 inhibitor class antidiabetic drug market. The market share held by generic versions of the original Galvus (vildagliptin) that were launched after the patent expiry of the original drug in March last year increased to 41% at the end of last year. The
1
2
3
4
5
6
7
8
9
10
>